Exploring the cellular heterogeneity underlying 'tumor-educated' platelets

Información del proyecto

PlateletLiquidBiopsy

Identificador del acuerdo de subvención: 753039

DOI

10.3030/753039

Proyecto finalizado el 31 Marzo 2019

Fecha de la firma de la CE 20 Marzo 2017

Fecha de inicio 1 Julio 2017

Fecha de finalización 30 Junio 2019

Financiado con arreglo a

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coste total

€ 159 460,80

Aportación de la UE

€ 159 460,80

Coordinado por

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Germany

Periodic Reporting for period 1 - PlateletLiquidBiopsy (Exploring the cellular heterogeneity underlying 'tumor-educated' platelets)

Período documentado: 2017-07-01 hasta 2019-06-30

Resumen del contexto y de los objetivos generales del proyecto

Cancer is one of the major causes of death worldwide. Early detection leads to treatment initiation in earlier cancer stages and therefore increases the chance of survival. However, appropriate diagnosis can be challenging because tissue acquisition of tumor samples for molecular testing often requires invasive procedures. To overcome these challenges researchers have focused on the real-time monitoring of molecules and cells in easily obtainable peripheral blood to gain diagnostic information. While many studies concentrated on the analysis of circulating tumor cells or tumor DNA, a recent study proposed the utilization of ‘tumor-educated’ platelets as a diagnostic biomarker in these ‘liquid biopsies’. However, the molecular mechanisms underlying this tumor education are unclear. How do these diverse tumors, originating from different parts of the body, affect the RNA content of platelets? The propose project focused on deciphering the origin of the tumor education signals by analyzing gene expression of single platelets from cancer patients and healthy control using single cell RNA sequencing (scRNAseq) technology. Despite promising results in other contexts, we were unable to obtain high quality scRNAseq data from platelets. Therefore, the researcher developed computational methods designed to improve analysis of scRNAseq data. The computational methods developed in this project and the application thereof to lung scRNAseq data were published in peer-reviewed journals. These findings will greatly benefit researchers using scRNAseq technology.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

To investigate the cellular landscape of tumor-educated platelets state-of-the-art sequencing technology was applied. Two collaboration partners were involved in the project. The Schiller group at the Comprehensive Pneumology Center at the Helmholtz Zentrum München has strong expertise in the generation of single-cell RNAseq data and successfully set up the, socalled Dropseq, single-cell RNAseq system. Additionally, the Petzold group from the Ludwigs-Maximilians Universität München has a strong expertise in platelet biology and provided the platelet RNA samples. To calibrate and validate our approach we purified platelet RNA from mice and humans and mixed the material. The so called “mixed species” experiment is a crucial quality control step in single-cell RNAseq data generation since it gives insight into the doublet and RNA capture rate of the experiment. The generated data showed very high doublet rates and very low RNA capture rates which hindered further analyses. Alternative approaches were discussed and we reached out to additional experts, but so far we were unable to generate good single platelet RNA expression data.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

Our results imply that single-cell RNA sequencing of platelets requires specialized single-cell RNA sequencing technology or elaborate calibration of existing technologies.

figure1.jpg